Figure 8 shows the metabolic pathway, affected by CYP2J4 and Ephx3 changes, on CKD progression. Decreased mRNA expression of CYP2C23 and CYP2E1 prevents the production of epoxyeicosatrienoic acids (EETs) as a vasodilator derived from arachidonic acid (AA). Increased mRNA expression of CYP2J4 induces the generation of EpOME as a protoxin, which is metabolized to DiHOME and involved in inflammation via the upregulation of Ephx3 as a soluble epoxide hydrolase (sEH). Here, CYP2E1 is linked to chronic kidney disease.